Iris
← Keeping up with Cancer Immunotherapy - Monthly Roundups by Iris
October 2026 roundupPeriod scanned: 2 October – 1 November 20265 min listen

MOIO trial fails to establish 12-week checkpoint dosing

Audio briefing

5 min

In this report
October added useful separation between early signals and clinical evidence: a phase III dosing strategy did not clear its interim non-inferiority test, while small studies produced signals in toxicity treatment, personalized vaccines and engineered cell therapy. The vaccine results also exposed a practical constraint: immune response and delivery feasibility are not the same endpoint.
  1. MOIO did not establish non-inferiority for checkpoint inhibitors given every 12 weeks, with a mortality hazard ratio of 2.00 versus standard schedules:
  2. A 30-patient phase Ib/II ECP study reported a 96.3% overall response rate in steroid-refractory immune-related adverse events, without severe adverse events:
  3. Early personalized-vaccine studies showed immune activity, but NeoVax manufacturing feasibility was 11% in newly diagnosed ovarian cancer and 75% in recurrent disease:
Clinical readouts and treatment strategy

MOIO trial fails to establish 12-week checkpoint dosing

General
The interim phase III MOIO analysis did not establish non-inferiority for 12-week checkpoint-inhibitor dosing, and the reduced-frequency arm had a mortality hazard ratio of 2.00 versus standard schedules. That makes treatment de-escalation an unresolved efficacy question rather than a convenience gain supported by this analysis.
  • The trial enrolled responding patients with advanced solid tumours; progression-free survival also favoured standard dosing, with a hazard ratio of 1.35.
  • Severe immune-related adverse events and serious adverse events were similar between the two groups, so the longer interval did not show a clear safety trade-off.
MOIO tests whether established checkpoint efficacy can be preserved when administration is deliberately reduced.

ECP reports responses in steroid-refractory irAEs

General
In a phase Ib/II study of 30 patients treated with immune checkpoint inhibitors, extracorporeal photopheresis produced a 96.3% overall response rate for steroid-refractory immune-related adverse events. The signal is substantial for a difficult toxicity setting, but it remains single-study evidence without randomized validation.
  • Response was 100% for colitis and dermatitis and 86.7% for hepatitis; the reported 12-month overall survival rate was 84.3%.
  • No severe adverse events were reported, while 20% of patients experienced ECP-related adverse events and inflammatory markers fell in peripheral T cells and intestinal tissue.
ECP extends immune-toxicity treatment beyond steroid escalation by targeting inflammatory activity after checkpoint therapy.
Personalized vaccines and delivery

NEC Bio expands individualized oral vaccine trial in TNBC

General
NEC Bio reported five pathological complete responses among the reported patients in NECVAX-NEO1, an individualized oral neoantigen therapy given with pembrolizumab and chemotherapy for triple-negative breast cancer. All reported patients showed immunogenic neoepitopes by ELISPOT, but the company presentation is an early, non-randomized readout rather than proof that the vaccine caused those responses.
  • The platform combines the IMMUNASIGHT neoantigen-prediction system with the TORAPRIME oral bacterial delivery system.
  • The study is expanding to 28 patients, including a US cohort after IND approval; the available report does not provide a comparator or mature clinical follow-up.
What this means for you
Translational vaccine work now has an expanding TNBC dataset linking individualized target selection with a defined oral delivery platform, not yet with comparative benefit.

NeoVax exposes manufacturing limits in ovarian cancer

General
The phase I NeoVax study generated tumour- and vaccine-specific immune responses in 6 of 10 patients with high-grade epithelial ovarian cancer, while manufacturing feasibility was only 11% in newly diagnosed disease. The result separates biological activity from whether a bespoke vaccine can be produced within the treatment timeline.
  • Feasibility was 75% in the recurrent-disease cohort, and more than 70% of selected neoantigen targets remained detectable after chemotherapy.
  • The vaccine was combined with delayed nivolumab; this small phase I study was not designed to establish clinical efficacy or survival benefit.
NeoVax tests the operational boundary between mutation-specific targeting and the compressed timelines of newly diagnosed ovarian cancer.
Cell therapy and shared-antigen vaccines

OX40 trispecific CAR-T shows early B-cell activity

General
A first-in-human phase I study of an OX40-enhanced CAR-T product targeting CD19, CD20 and CD22 reported remissions across B-cell malignancies, with manufacturing and infusion completed within six days. The early activity and short production interval are notable for a treatment-resistant population, but the small uncontrolled study cannot establish comparative efficacy.
  • Clinical activity was reported in mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma, with minimal side effects in the available account.
  • The product's three-antigen design and OX40 enhancement are intended to address antigen escape and persistence, but larger trials are needed to test both claims.
This CAR-T construct combines antigen breadth, OX40 costimulation and rapid production in one first-in-human test.

BNT113 fails to delay head and neck progression

General
BioNTech's HPV16 mRNA vaccine BNT113 did not significantly delay progression in a phase II/III head and neck cancer trial. The result adds a negative clinical readout to a class that can reliably generate T-cell responses without consistently improving tumour outcomes.
  • The vaccine targets a shared HPV16 antigen, unlike the individualized neoantigen approaches reported elsewhere this month.
  • The report points to patient selection, treatment setting and overall survival as unresolved considerations; it does not establish that any one of them rescues the approach.
BNT113 directly tests whether a reproducible shared-antigen T-cell response translates into delayed progression.
How Iris covered your topics this month
Every topic you track was searched over the last month.
TopicSources foundIn this briefing
General346 stories
Appendix: 34 sources relevant to you, from 57 scanned
General · 34
The Addition of Concurrent Immune Checkpoint... : International Journal Of Cancer · ovid.com · 2026-11-01Research
Recent advances and future challenges of bispecific antibodies in lung cancer · sciencedirect.com · 2026-11-01Research
Designing Precision Vaccines for Cancer Immunotherapy · dergipark.org.tr · 2026-10-30News
120 studies later: what we know about vaccines for pancreatic cancer · unil.ch · 2026-10-30News
CAR-T Cell Therapy: What You Need to Know | International Myeloma Foundation · myeloma.org · 2026-10-27News
Why Lung Cancer Vaccines Are Worth Watching · go2.org · 2026-10-27News
Bispecific Antibodies Nursing Resources · bccancer.bc.ca · 2026-10-27News
MOIO Trial: Can Immunotherapy Be Given Less Frequently? - OncoDaily · oncodaily.com · 2026-10-26News
Programmable mRNA vaccine materials for temporal control of antitumour immunity | Nature Reviews Materials · nature.com · 2026-10-26Research
Milestone cancer vaccine success leaves hard questions unanswered | Science | AAAS · science.org · 2026-10-26News
Promising New Results for Melanoma mRNA Vaccine | Memorial Sloan Kettering Cancer Center · mskcc.org · 2026-10-23News
Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial | Nature Communications · nature.com · 2026-10-23Research
Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation | Experimental Hematology & Oncology | Springer Nature Link · link.springer.com · 2026-10-22Research
The cancer vaccine landscape: What to know · beckershospitalreview.com · 2026-10-22News
NEC Presents Results for Individualized Neoantigen Therapy NECVAX-NEO1 at ESMO 2026: Press Releases | NEC · nec.com · 2026-10-22News
Efficacy and Safety of Immune Checkpoint Inhibitors ... · cancernetwork.com · 2026-10-21News
ESMO 2026: 5 Phase III Immunotherapy Trials to Watch - OncoDaily · oncodaily.com · 2026-10-20News
Shared-Antigen Cancer Vaccines Keep Falling Short | Cancer Discovery | American Association for Cancer Research · aacrjournals.org · 2026-10-20Research
T-cell engagers in multiple myeloma: Structural design and clinical op | DDDT | Dove Medical Press · dovepress.com · 2026-10-19Research
In vivo CAR T-cell therapy: a systematic review of clinical trials | BMC Cancer | Springer Nature Link · link.springer.com · 2026-10-16Research
CAR-T Cell Therapy Moves Beyond Cancer to Autoimmune Diseases | News | Yale Medicine · yalemedicine.org · 2026-10-16News
Personalized neoantigen vaccine for ovarian cancer: what the phase 1 trial found · bitesofbio.com · 2026-10-14News
Immune checkpoint inhibitors across neoadjuvant, perioperative, and adjuvant settings for resectable non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials | JoVE Visualize · visualize.jove.com · 2026-10-13Research
Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial · medicalxpress.com · 2026-10-13News
Scientists identify clues to making immunotherapy more effective against glioblastoma · stemcell.ucla.edu · 2026-10-13Announcement
Bispecific Antibody Therapy at New Jersey Cancer Care  - New Jersey Cancer Care, PA · njcancercare.org · 2026-10-12News
The Bispecific Antibody Landscape at ESMO 2026 · delveinsight.com · 2026-10-09News
NCT05805501 | A Study of Immune Checkpoint Inhibitor ... · clinicaltrials.gov · 2026-10-08Official
Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting | Journal of Hematology & Oncology | Springer Nature Link · link.springer.com · 2026-10-07Research
Precision targeting and alternative effector cells: revolutionizing CAR-based therapy for T-cell malignancies | Clinical and Experimental Immunology | Oxford Academic · academic.oup.com · 2026-10-06Research
Safe Outpatient Delivery of Bispecific Antibodies · ons.org · 2026-10-06News
ACCC | The Financial Reality of Bispecific Antibodies: What It Takes to Build and Sustain a Program - Podcast [Ep. 243] · accc-cancer.org · 2026-10-06News
Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma | Clinical Trials | Yale Medicine · yalemedicine.org · 2026-10-04News
Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials: Expert Review of Anticancer Therapy: Vol 26 , No 10 - Get Access · tandfonline.com · 2026-10-03Research
23 more scanned and set aside
General News Today — October 31, 2026 — NewsChatter.com · newschatter.com · 2026-10-31News
World News - The New York Times International · nytimes.com · 2026-10-31News
While You Were Sleeping: 5 stories you might have missed, No… · straitstimes.com · 2026-10-31News
Global News Highlights from AP | 無綫新聞 TVB News · news.tvb.com · 2026-10-31News
News items | The United Nations Office at Geneva · ungeneva.org · 2026-10-31News
Latest News | 1 UN News · news.un.org · 2026-10-31Low signal
Bispecific Antibodies · genentech-medinfo.com · 2026-10-29News
NBC News - Breaking Headlines and Video Reports on World, U.… · nbcnews.com · 2026-10-29News
News Releases | Washington State · atg.wa.gov · 2026-10-29Official
Hegseth fires top general over apparent media leaks - CBS News · cbsnews.com · 2026-10-29News
Rising to the challenge: CAR T’s future in haematological ca… · iqvia.com · 2026-10-28News
Immune Checkpoint Inhibitor Reactions in the Out-of-Hospital… · jems.com · 2026-10-27News
News | Today's latest from Al Jazeera · aljazeera.com · 2026-10-27News
CAR T-Cell Therapy Shows Promising Initial Results in MS · consultqd.clevelandclinic.org · 2026-10-26News
Associated Press News: Breaking News · apnews.com · 2026-10-21News
CAR-T-centered sequential therapy: current status, challenge… · link.springer.com · 2026-10-16Research
Targeted Antibodies · cancerresearch.org · 2026-10-16News
Cancer Vaccines: An In-Depth Guide · cancerresearch.org · 2026-10-16News
Bispecific Antibody Therapy | Huntsman Cancer Institute · healthcare.utah.edu · 2026-10-15News
Personalized Cancer Vaccine Market (2026 - 2033) · grandviewresearch.com · 2026-10-12Low signal
NewsForKids.net – Real News, Told Simply.™ · newsforkids.net · 2026-10-11News
Frontiers | CAR-T cell therapy for solid tumors: antigen lan… · frontiersin.org · 2026-10-09Research
CAR T cells for autoimmune diseases: 2026 update of the EBMT… · sciencedirect.com · 2026-10-05Research
Tell Iris what to cover more, less, or differently. It shapes your next briefing.
This briefing was generated by Iris Briefings.
Iris uses artificial intelligence to synthesise recent developments in your field. It can make mistakes, so please verify anything critical against the linked primary sources before acting on it. Thank you for supporting Iris.

Want this for your field?

Iris builds a briefing agent around your own profile: your field, your focus areas, your context. Delivered on your schedule.

Get your own briefing

Iris is a tool that uses AI to find publicly available information and extract the insights that matter for you. Iris Briefings have taken precautions to ensure our systems are robust but these are not infallible. Nothing in your briefings should be taken for medical, legal or professional advice and Iris cannot take responsibility for your decisions. We encourage you to do your own due diligence on the primary sources that Iris references for critical decisions.